Ocular Therapeutix, Inc.

OCUL

US67576A1007

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
5.795 ^USD	-0.09%		-6.08%	+29.93%

16/05	Transcript : Ocular Therapeutix, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
07/05	Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	MT

Ocular Therapeutix, Inc. Announces Resignation of Bruce A. Peacock as Member of the Board of Directors

February 08, 2022 at 03:32 am IST

Ocular Therapeutix, Inc. announced on February 3, 2022, Bruce A. Peacock notified company that he planned to resign as a member of the Board of Directors on the date of the Company's annual meeting of stockholders to be held in 2022.

Latest news about Ocular Therapeutix, Inc.

Transcript : Ocular Therapeutix, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM	16/05
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	08/05	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	19/04	DJ
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	19/04	MT
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18/04	CI
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	15/04	MT
Ocular Therapeutix, Inc. Announces Executive Changes	15/04	CI
Ocular Therapeutix, Inc. Announces CEO Changes	15/04	CI
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	06/04	CI
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours	26/03	MT
Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to S&P Pharmaceuticals Select Industry Index	18/03	CI
HC Wainwright Adjusts Price Target on Ocular Therapeutix to $15 From $12, Keeps Buy Rating	13/03	MT
TD Cowen Adjusts Price Target on Ocular Therapeutix to $11 From $8, Maintains Market Perform Rating	12/03	MT
JMP Securities Adjusts Ocular Therapeutix's Price Target to $24 From $12, Maintains Market Outperform Rating	12/03	MT
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours	12/03	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03	CI
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q4 Revenue $14.8M, vs. Street Est of $15.7M	12/03	MT
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03	CI
North American Morning Briefing : Stock Futures -2-	11/03	DJ
Ocular Therapeutix, Inc. announced that it has received $324.999962 million in funding from a group of investors	05/03	CI
Piper Sandler Adjusts Ocular Therapeutix Price Target to $15 From $10, Maintains Overweight Rating	26/02	MT
Ocular Therapeutix Launches $325 Million Private Placement; Makes Board, Management Changes, Shares Rise	22/02	MT
Ocular Therapeutix, Inc. Announces Management Changes	22/02	CI
Ocular Therapeutix, Inc. announced that it expects to receive $324.999962 million in funding	21/02	CI

Chart Ocular Therapeutix, Inc.

Duration

Period

More charts

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).

Sector

Pharmaceuticals

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ocular Therapeutix, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.795 USD

Average target price

14.5 USD

Spread / Average Target

+150.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OCULAR THERAPEUTIX, INC.	+29.93%	898M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals